Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 20.23% | 4.93% | -5.92% | 21.86% | -1.06% |
| Total Depreciation and Amortization | -19.83% | 28.00% | -5.88% | 3.66% | 52.63% |
| Total Amortization of Deferred Charges | 0.00% | -7.69% | 10.00% | 9.09% | 14.29% |
| Total Other Non-Cash Items | 117.76% | -57.44% | 3.11% | -102.19% | 0.41% |
| Change in Net Operating Assets | 54.98% | -36,928.85% | -23.37% | -8.90% | -512.99% |
| Cash from Operations | 38.97% | -53.18% | -14.64% | 14.96% | -44.97% |
| Capital Expenditure | -- | 100.00% | -497.22% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.35% | -100.00% | -33.62% | 42.53% | 2,094.06% |
| Cash from Investing | -101.38% | -100.00% | -34.25% | 43.27% | 2,248.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.88% | -2.21% | 0.45% | -6.02% | -4.63% |
| Issuance of Common Stock | -75.63% | 429.47% | 353.17% | -79.51% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -75.81% | 501.26% | 356.74% | -119.47% | 44,362.04% |
| Foreign Exchange rate Adjustments | -199.46% | 364.73% | -88.23% | -1,252.34% | 113.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.14% | -138.50% | 1,793.89% | 12.62% | 311.01% |